{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T10:09:03Z","timestamp":1775470143456,"version":"3.50.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess belimumab efficacy in patients from North East Asia (NEA) with systemic lupus erythematosus (SLE) in baseline demographic\/disease characteristic subgroups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This analysis of patient subgroups from BLISS-NEA (GSK Study 113750; NCT01345253) studied adults with SLE randomized to belimumab (10\u2009mg\/kg intravenous) or placebo. Primary endpoint, SLE Responder Index 4 (SRI-4) response rate at Week 52, was analysed in subgroups defined by gender, country, prednisone-equivalent dose, concomitant medications, Safety of Estrogens in Lupus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI) score, complement (C) levels, anti-double-stranded deoxyribonucleic acid (dsDNA) positivity, Systemic Lupus International Collaborating Clinics\/American College of Rheumatology Damage Index score.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Patients (overall population: N\u2009=\u2009677; belimumab: n\u2009=\u2009451, placebo: n\u2009=\u2009226) were from China (76.4%), Korea (14.8%), and Japan (8.9%). The mean age was 32.1\u2009years; 92.9% were female. In the overall population, more belimumab (53.8%) than placebo (40.1%) patients were SRI-4 Week 52 responders (p\u2009=\u2009.0001). SRI-4 response rates by subgroups were generally consistent with the overall population. A greater response with belimumab was seen in patients with a baseline SELENA-SLEDAI score \u226510 versus \u22649 and patients with low C3\/C4 levels and anti-dsDNA positive at baseline versus those \u2018NOT\u2019 (low C3 and\/or C4 and anti-dsDNA positive).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These findings continue to support the efficacy of belimumab in SLE.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roac076","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T14:27:22Z","timestamp":1665239242000},"page":"751-757","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of belimumab in patients with systemic lupus erythematosus from North East Asia: Results of exploratory subgroup analyses"],"prefix":"10.1093","volume":"33","author":[{"given":"Jie","family":"Zheng","sequence":"first","affiliation":[{"name":"Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieruo","family":"Gu","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital of Sun Yat-Sen University , Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Su","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital , Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital, Harbin Medical University , Harbin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingfu","family":"Li","sequence":"additional","affiliation":[{"name":"Qilu Hospital of Shandong University , Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cui","family":"Xiong","sequence":"additional","affiliation":[{"name":"GSK , Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Cao","sequence":"additional","affiliation":[{"name":"Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Quasny","sequence":"additional","affiliation":[{"name":"GSK , Research Triangle Park, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myron","family":"Chu","sequence":"additional","affiliation":[{"name":"GSK , Collegeville, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Curtis","sequence":"additional","affiliation":[{"name":"GSK , Brentford, Middlesex, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"DeRose","sequence":"additional","affiliation":[{"name":"GSK , Collegeville, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Kurrasch","sequence":"additional","affiliation":[{"name":"GSK , Collegeville, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paige","family":"Meizlik","sequence":"additional","affiliation":[{"name":"GSK , Collegeville, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A","family":"Roth","sequence":"additional","affiliation":[{"name":"GSK , Collegeville, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3484-4319","authenticated-orcid":false,"given":"Fengchun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,10,8]]},"reference":[{"key":"2023070502120178200_R1","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.molmed.2017.05.006","article-title":"Pathogenesis of human systemic lupus erythematosus: a cellular perspective","volume":"23","author":"Moulton","year":"2017","journal-title":"Trends Mol Med"},{"key":"2023070502120178200_R2","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/bor.0000000000000480","article-title":"Epidemiology of systemic lupus erythematosus: an update","volume":"30","author":"Stojan","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"2023070502120178200_R3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.semarthrit.2008.10.007","article-title":"Understanding the epidemiology and progression of systemic lupus erythematosus","volume":"39","author":"Pons-Estel","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"2023070502120178200_R4","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1177\/0961203313499086","article-title":"Chinese SLE treatment and research group (CSTAR) registry: I. Major clinical characteristics of Chinese patients with systemic lupus erythematosus","volume":"22","author":"Li","year":"2013","journal-title":"Lupus"},{"key":"2023070502120178200_R5","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1002\/art.11299","article-title":"Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator","volume":"48","author":"Baker","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2023070502120178200_R6","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2023070502120178200_R7","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/s0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"2023070502120178200_R8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","article-title":"A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea","volume":"77","author":"Zhang","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023070502120178200_R9","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2023070502120178200_R10","article-title":"Benlysta: Summary of Product Characteristics","author":"EMA","year":"2021"},{"key":"2023070502120178200_R11","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response","volume":"71","author":"van Vollenhoven","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2023070502120178200_R12","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2023070502120178200_R13","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/art.40511","article-title":"Efficacy and safety of subcutaneous belimumab in anti-double-stranded DNA-positive, hypocomplementemic patients with systemic lupus erythematosus","volume":"70","author":"Doria","year":"2018","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2023070502120178200_R14","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2023070502120178200_R15","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000459","article-title":"Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme","volume":"8","author":"Maslen","year":"2021","journal-title":"Lupus Sci Med"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac076\/46825050\/roac076.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/4\/751\/50797215\/roac076.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/4\/751\/50797215\/roac076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T03:03:21Z","timestamp":1688526201000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/33\/4\/751\/6754227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,8]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,10,8]]},"published-print":{"date-parts":[[2023,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac076","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2022,10,8]]}}}